IP Library Granted Patent US 11,548,872
Granted Patent B2
US 11,548,872 · App. 17/155,577 · Granted Jan 10, 2023

Isoquinolin-3-yl carboxamides and preparation and use thereof

Inventors: Sunil Kumar KC (San Diego, CA); Chi Ching Mak (San Diego, CA); Brian Walter Eastman (San Diego, CA); Jianguo Cao (San Diego, CA); Venkataiah Bollu (San Diego, CA); Gopi Kumar Mittapalli (San Diego, CA); Chandramouli Chiruta (San Diego, CA)
Assignee: BioSplice Therapeutics, Inc.
C07D401/14C07D401/04C07D405/14C07D409/14C07D413/14C07D417/04C07D417/14C07D471/08C07D471/10C07D487/04C07D487/08C07D491/048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,548,872
App. No.
17/155,577
Granted
Jan 10, 2023
Kind
B2
Abstract

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Claims (123)

1. A method of treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: a bone or cartilage disease, osteoarthritis, and degenerative disc disease, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof:

wherein:

R 1 , R 2 , R 4 , and R 5 are independently selected from the group consisting of H, halide, amino, unsubstituted —(C 1-3 haloalkyl), and unsubstituted —(C 1-3 alkyl);

R 3 is selected from the group consisting of:

wherein each of R 7 -R 35 is, independently, a substituent as defined anywhere herein or a single bond connecting R 3 to the isoquinoline ring; wherein only one of R 7 -R 10 (when present) is a bond, only one of R 11 -R 14 (when present) is a bond, only one of R 15 -R 17 (when present) is a bond, only one of R 18 -R 20 (when present) is a bond, only one of R 21 -R 23 (when present) is a bond, only one of R 24 -R 26 (when present) is a bond, only one of R 27 -R 29 (when present) is a bond, only one of R 30 -R 31 (when present) is a bond, only one of R 32 -R 33 (when present) is a bond, and only one of R 34 -R 35 (when present) is a bond; wherein any one of the nitrogen atoms attached to R 7 , R 11 , R 15 , R 18 , or R 21 can serve as the point of attachment of R 3 to the isoquinoline ring; wherein any one of the carbon atoms attached to R 8 , R 9 , R 10 , R 12 , R 13 , R 14 , R 16 , R 17 , R 19 , R 20 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , or R 35 can serve as the point of attachment of R 3 to the isoquinoline ring; as that:

when the nitrogen atom to which R 7 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 7 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 8 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 8 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 9 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 9 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 10 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 10 is a single bond connecting R 3 to the isoquinoline ring;

when the nitrogen atom to which R 11 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 11 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 12 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 12 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 13 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 13 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 14 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 14 is a single bond connecting R 3 to the isoquinoline ring;

when the nitrogen atom to which R 15 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 15 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 16 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 16 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 17 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 17 is a single bond connecting R 3 to the isoquinoline ring;

when the nitrogen atom to which R 18 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 18 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 19 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 19 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 20 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 20 is a single bond connecting R 3 to the isoquinoline ring;

when the nitrogen atom to which R 21 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 21 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 22 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 22 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 23 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 23 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 24 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 24 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 25 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 25 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 26 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 26 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 27 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 27 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 28 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 28 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 29 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 29 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 30 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 30 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 31 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 31 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 32 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 32 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 33 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 33 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 34 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 34 is a single bond connecting R 3 to the isoquinoline ring;

when the carbon atom to which R 35 is attached serves as the point of attachment of R 3 to the isoquinoline ring, then R 35 is a single bond connecting R 3 to the isoquinoline ring;

R 6 is selected from the group consisting of -phenyl substituted with 1-5 R 36 , —(C 1-3 alkylene) p pyridinyl optionally substituted with 1-6 R 37 , and a 6-10 membered heteroaryl optionally substituted with 1-6 R 37 ; wherein the carbonyl of Formula I is attached to an aromatic ring of the heteroaryl; wherein —(C 1-3 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;

R 7 is selected from the group consisting of a single bond, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene)N(R 48 ) 2 , —(C 1-4 alkylene)OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein —(C 1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;

R 8 , R 9 , and R 10 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, one of R 7 and R 8 , R 8 and R 9 , or R 9 and R 10 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

R 11 is selected from the group consisting of a single bond, H, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene)N(R 48 ) 2 , —(C 1-4 alkylene)OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein —(C 1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;

R 12 , R 13 , and R 14 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, one of R 11 and R 12 , R 12 and R 13 , or R 14 and R 11 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

R 15 is selected from the group consisting of a single bond, H, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene)N(R 48 ) 2 , —(C 1-4 alkylene)OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein —(C 1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;

R 16 and R 17 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, one of R 15 and R 16 or R 16 and R 17 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

R 18 is selected from the group consisting of a single bond, H, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene)N(R 48 ) 2 , —(C 1-4 alkylene)OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein —(C 1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;

R 19 and R 20 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, one of R 18 and R 19 or R 18 and R 20 are taken together to form a heterocyclyl optionally substituted with 1-10 R 40 ;

R 21 is selected from the group consisting of a single bond, H, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene)N(R 48 ) 2 , —(C 1-4 alkylene)OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein —(C 1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;

R 22 and R 23 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, R 22 and R 23 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

R 24 , R 25 , and R 26 are independently selected from the group consisting of a single bond, H, halide,

unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, one of R 24 and R 25 or R 25 and R 26 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

R 27 , R 28 , and R 29 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, R 27 and R 28 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

R 30 and R 31 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, R 30 and R 31 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

R 32 and R 33 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

R 34 and R 35 are independently selected from the group consisting of a single bond, H, halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —(C 1-4 alkylene) p N(R 48 ) 2 , —(C 1-4 alkylene) p OR 49 , —C(═O)N(R 48 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 38 , and -carbocyclyl optionally substituted with 1-12 R 39 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, R 34 and R 35 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R 40 and -carbocyclyl optionally substituted with 1-12 R 41 ;

each R 36 is independently selected from the group consisting of halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —XR 42 , —C(═O)N(R 47 ) 2 , —(C 1-4 alkylene) p N(R 50 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 43 , and —(C 1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 44 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 37 is independently selected from the group consisting of halide, unsubstituted —(C 1-9 alkyl), unsubstituted —(C 2-9 alkenyl), unsubstituted —(C 2-9 alkynyl), unsubstituted —(C 1-9 haloalkyl), —XR 42 , —C(═O)N(R 47 ) 2 , —(C 1-4 alkylene) p N(R 50 ) 2 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 43 , and —(C 1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 44 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 38 is independently selected from the group consisting of halide, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), —CN, and —(C 1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 44 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 39 is independently selected from the group consisting of halide, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), —CN, and —(C 1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 44 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 40 is independently selected from the group consisting of halide, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), —CN, and —(C 1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 44 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 41 is independently selected from the group consisting of halide, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), and —CN;

each R 42 is independently selected from the group consisting of H, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), —(C 1-4 alkylene)N(R 48 ) 2 , —(C 1-4 alkylene) p aryl optionally substituted with 1-10 R 46 , —(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-12 R 43 , and —(C 1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 44 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 43 is independently selected from the group consisting of halide, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), —CN, —OH, —C(═O)R 51 , —N(R 50 ) 2 , and —(C 1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 44 ; wherein each —(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 44 is selected from the group consisting of halide, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), and —CN;

each R 46 is independently selected from the group consisting of halide, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), and —CN;

each R 47 is independently selected from the group consisting of H, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), and unsubstituted —(C 1-5 haloalkyl);

each R 48 is independently selected from the group consisting of H, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), and unsubstituted —(C 1-5 haloalkyl);

each R 49 is independently selected from the group consisting of H, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), and unsubstituted —(C 1-5 haloalkyl);

each R 50 is independently selected from the group consisting of H, unsubstituted —(C 1-5 alkyl), unsubstituted —(C 2-5 alkenyl), unsubstituted —(C 2-5 alkynyl), unsubstituted —(C 1-5 haloalkyl), and —(C 1-4 alkylene)N(R 48 ) 2 ; wherein —(C 1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;

each R 51 is a heteroaryl optionally substituted with 1-6 R 52 ;

each R 52 is a -heterocyclyl optionally substituted with 1-10 R 46 ;

each X is selected from the group consisting of 0, S, and NR 48 ;

each Y is selected from the group consisting of 0 and S;

each p is independently 0 or 1, and

wherein each H atom is optionally independently replaced by 2 H (deuterium).

2. The method of claim 1 , wherein R 1 , R 2 , R 4 , and R 5 are H.

3. The method of claim 2 , wherein R 3 is selected from the group consisting of:

4. The method of claim 3 , wherein R 3 is selected from the group consisting of:

wherein R 7 , R 11 , R 14 , R 15 , R 18 , and R 19 are independently selected from the group consisting of H and —(C 1-3 alkyl).

5. The method of claim 4 , wherein R 3 is

wherein R 7 is —(C 1-3 alkyl).

6. The method of claim 1 wherein R 6 is -phenyl substituted with 1-5 R 36 .

7. The method of claim 4 wherein R 6 is -phenyl substituted with 1-5 R 36 .

8. The method of claim 5 , wherein R 6 is -phenyl substituted with 1-5 R 36 .

9. The method of claim 6 , wherein R 6 is -phenyl substituted with one R 36 .

10. The method of claim 7 , wherein R 6 is -phenyl substituted with one R 36 .

11. The method of claim 8 , wherein R 6 is -phenyl substituted with one R 36 .

12. The method of claim 9 , wherein R 36 is selected from the group consisting of halide, -heterocyclyl optionally substituted with 1-2 R 43 , —CH 2 heterocyclyl optionally substituted with 1-2 R 43 , —Oheterocyclyl optionally substituted with 1-2 R 43 , —NHheterocyclyl optionally substituted with 1-2 R 43 , —O(C 1-4 alkyl), and —O(C 1-4 haloalkyl).

13. The method of claim 10 , wherein R 36 is selected from the group consisting of halide, -heterocyclyl optionally substituted with 1-2 R 43 , —CH 2 heterocyclyl optionally substituted with 1-2 R 43 , —Oheterocyclyl optionally substituted with 1-2 R 43 , —NHheterocyclyl optionally substituted with 1-2 R 43 , —O(C 1-4 alkyl), and —O(C 1-4 haloalkyl).

14. The method of claim 11 , wherein R 36 is selected from the group consisting of halide, -heterocyclyl optionally substituted with 1-2 R 43 , —CH 2 heterocyclyl optionally substituted with 1-2 R 43 , —Oheterocyclyl optionally substituted with 1-2 R 43 , —NHheterocyclyl optionally substituted with 1-2 R 43 , —O(C 1-4 alkyl), and —O(C 1-4 haloalkyl).

15. The method of claim 1 , wherein R 6 is a 6-membered heteroaryl optionally substituted with 1-6 R 37 .

16. The method of claim 4 , wherein R 6 is a 6-membered heteroaryl optionally substituted with 1-6 R 37 .

17. The method of claim 5 , wherein R 6 is a 6-membered heteroaryl optionally substituted with 1-6 R 37 .

18. The method of claim 15 , wherein R 6 is -pyridin-3-yl optionally substituted with one R 37 .

19. The method of claim 16 , wherein R 6 is -pyridin-3-yl optionally substituted with one R 37 .

20. The method of claim 17 , wherein R 6 is -pyridin-3-yl optionally substituted with one R 37 .

21. The method of claim 15 , wherein R 6 is -pyridin-4-yl optionally substituted with one R 37 .

22. The method of claim 16 , wherein R 6 is -pyridin-4-yl optionally substituted with one R 37 .

23. The method of claim 17 , wherein R 6 is -pyridin-4-yl optionally substituted with one R 37 .

24. The method of claim 21 , wherein R 37 is selected from the group consisting of halide, —(C 1-3 alkyl), -heterocyclyl optionally substituted with 1-2 R 43 , —CH 2 heterocyclyl optionally substituted with 1-2 R 43 , —Oheterocyclyl optionally substituted with 1-2 R 43 , —NHheterocyclyl optionally substituted with 1-2 R 43 , —O(C 1-4 alkyl), and —O(C 1-4 haloalkyl).

25. The method of claim 22 , wherein R 37 is selected from the group consisting of halide, —(C 1-3 alkyl), -heterocyclyl optionally substituted with 1-2 R 43 , —CH 2 heterocyclyl optionally substituted with 1-2 R 43 , —Oheterocyclyl optionally substituted with 1-2 R 43 , —NHheterocyclyl optionally substituted with 1-2 R 43 , —O(C 1-4 alkyl), and —O(C 1-4 haloalkyl).

26. The method of claim 23 , wherein R 37 is selected from the group consisting of halide, —(C 1-3 alkyl), -heterocyclyl optionally substituted with 1-2 R 43 , —CH 2 heterocyclyl optionally substituted with 1-2 R 43 , —Oheterocyclyl optionally substituted with 1-2 R 43 , —NHheterocyclyl optionally substituted with 1-2 R 43 , —O(C 1-4 alkyl), and —O(C 1-4 haloalkyl).

27. The method of claim 24 , wherein R 43 is selected from the group consisting of unsubstituted —(C 1-3 alkyl), unsubstituted —(C 1-3 haloalkyl), and -carbocyclyl optionally substituted with 1-12 R 44 .

28. The method of claim 25 , wherein R 43 is selected from the group consisting of unsubstituted —(C 1-3 alkyl), unsubstituted —(C 1-3 haloalkyl), and -carbocyclyl optionally substituted with 1-12 R 44 .

29. The method of claim 26 , wherein R 43 is selected from the group consisting of unsubstituted —(C 1-3 alkyl), unsubstituted —(C 1-3 haloalkyl), and -carbocyclyl optionally substituted with 1-12 R 44 .

30. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

31. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

32. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

33. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

34. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

35. The method of claim 1 , wherein the disorder or disease is a bone or cartilage disease.

36. The method of claim 1 , wherein the disorder or disease is osteoarthritis.

37. The method of claim 1 , wherein the disorder or disease is degenerative disc disease.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2026
From: BIOSPLICE THERAPEUTICS, INC.
To: TENARX, INC.
Reel/Frame 074209/0693 →
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2026
From: TMF GROUP NEW YORK, LLC, NOT INDIVIDUALLY BUT SOLELY AS COLLATERAL AGENT
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 075109/0434 →
SECURITY INTEREST Recorded Sep 14, 2022
From: BIOSPLICE THERAPEUTICS, INC.
To: VICKERS VENTURE FUND VI PTE. LTD.; VICKERS VENTURE FUND VI (PLAN) PTE. LTD.; VICKERS-SPLICE CO-INVESTMENT LLC; MED-PATHWAYS II LIMITED
Reel/Frame 061433/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2021
From: SAMUMED, LLC
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 055694/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2021
From: KC, SUNIL KUMAR; MAK, CHI CHING; EASTMAN, BRIAN WALTER; CAO, JIANGUO; BOLLU, VENKATAIAH; MITTAPALLI, GOPI KUMAR; CHIRUTA, CHANDRAMOULI
To: SAMUMED, LLC
Reel/Frame 055013/0686 →
Continuity (5)
Continuation 16703321 · Dec 4, 2019
Continuation 16130842 · Sep 13, 2018
Continuation 15499013 · Apr 27, 2017
Provisional Application 62328255 · Apr 27, 2016
Related Publication 20220332698A1 · Oct 20, 2022
Cited By (1)
US 12,281,097